Skip to main content
. 2015 Mar 10;32(3):254–269. doi: 10.1007/s12325-015-0192-6

Table 5.

Base-case cost-effectiveness analysis of MFNS versus BDNS for pediatric allergic rhinitis treatment

Category Strategy Cost (US$) Incremental cost (US$) Effectiveness (TIX score) Incremental effectiveness (TIX score) Cost/effectiveness
MFNS 229.78 0.9724 236.31
Absolutely dominated BDNS 289.74 59.96 0.8712 −0.1012 332.58

BDNS beclomethasone dipropionate nasal spray, MFNS mometasone furoate nasal spray, TIX therapeutic index